Lantheus Holdings Inc
NASDAQ:LNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lantheus Holdings Inc
Other Current Liabilities
Lantheus Holdings Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Other Current Liabilities
$40.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
87%
|
CAGR 10-Years
37%
|
|
|
Figs Inc
NYSE:FIGS
|
Other Current Liabilities
$22.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Other Current Liabilities
$134.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Other Current Liabilities
$96.6m
|
CAGR 3-Years
38%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Other Current Liabilities
$1.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Other Current Liabilities
$8.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
9%
|
|
Lantheus Holdings Inc
Glance View
Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.
See Also
What is Lantheus Holdings Inc's Other Current Liabilities?
Other Current Liabilities
40.8m
USD
Based on the financial report for Dec 31, 2025, Lantheus Holdings Inc's Other Current Liabilities amounts to 40.8m USD.
What is Lantheus Holdings Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
37%
Over the last year, the Other Current Liabilities growth was 303%. The average annual Other Current Liabilities growth rates for Lantheus Holdings Inc have been 21% over the past three years , 87% over the past five years , and 37% over the past ten years .